Among many agents developed to target NFκB pathways, very few drugs have received approval for administration in AML patients so far [83], suggesting that there are complexities and challenges in clinical drug development rather than the proof-of-concept exploration of a NFκB2 inhibitor in the present study. This evidence concerns the gene NFKB2 and acute myeloid leukemia.